companydata.dkDraupnir Bio ApS: Financial statements 2021
CVR: 38546880
Draupnir Bio ApS (CVR 38546880) has filed annual accounts for 2021. In 2021, the company reported a net result of DKK -67,044,000 compared with DKK -60,620,000 the year before. Equity amounted to DKK 53,466,000. The solvency ratio was 78.8%.
- Profit/Loss
- -67,044,000 kr.
- Equity
- 53,466,000 kr.
- Total Assets
- 67,865,000 kr.
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | - | -67 mio. | 53.5 mio. | - |
| 2020 | - | - | -60.6 mio. | 54.2 mio. | - |
| 2019 | - | -15.9 mio. | -15.2 mio. | 52 mio. | 2 |
| 2018 | - | -1.8 mio. | -2.1 mio. | -1.8 mio. | 1 |
Find more companies like Draupnir Bio ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2021
Draupnir Bio ApS has published its annual report for 2020. The net result was DKK -60,620,000.
As of June 9, 2021, Emmanuelle Coutanceau has joined the board of directors of Draupnir Bio ApS.
As of June 9, 2021, Eva-Lotta Coulter has joined the board of directors of Draupnir Bio ApS.
As of June 8, 2021, Emmanuelle Coutanceau has left the board of directors of Draupnir Bio ApS.
As of June 1, 2021, Andrew Thomas Hotchkiss is registered as director of Draupnir Bio ApS.
As of June 1, 2021, Simon Glerup Pedersen has stepped down as director of Draupnir Bio ApS.
About Draupnir Bio ApS
Draupnir Bio ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Andrew Thomas Hotchkiss. The company's owners include Novo Holdings A/S, Coöperatieve Gilde Healthcare IV U.A. and Danmarks Eksport- og Investeringsfond. Equity amounted to DKK 15,256,000.